HS Bio Sdn Bhd, a wholly-owned subsidiary of Hong Seng, entered into a collaboration agreement with Mediven Innovation Ventures (Mediven) to jointly cooperate and collaborate on the provisioning of healthcare products and services through their respective network and capabilities subject to the terms and conditions of the agreement.
As stated in the agreement, both parties are collaborating and co-operating with each other to expand their respective coverage in the healthcare sector by leveraging each other’s strengths, skills, experience, know-how, network, and capabilities.
HS Bio is in the business of providing integrated healthcare solutions that applies proven digital know-how and end-to-end supply chain management, including but not limited to digital health, laboratory testing services, research and development services as well as the provision of medical and healthcare supplies for both private and public sectors.
Mediven is a molecular diagnostics provider in Malaysia, delivering fast, flexible, reliable, and intelligent solutions with its GenoAmpTM and ProDetectTM series of products. It has built a stellar reputation for the design, development, and manufacture of innovative diagnostic products for infectious diseases, with strong collaborative ties with research institutions both locally and abroad.
“We find that Mediven’s proven quality in internationally-recognised assessments, as well as its success in executing projects and exporting its products, will certainly lend us a great hand in bidding for new projects and gaining exposure in overseas markets.,” Hong Seng executive director and HS Bio director Christopher Chan said.
“We believe that by combining our strengths as a leading molecular diagnostics provider in Malaysia with HS Bio’s wide-reaching healthcare supply chain solutions, both parties will be able to make a significant impact in improving health and preventing infectious diseases.,” Mediven Operations Director Dr Lim Li Sze commented
HS Bio and its healthcare subsidiaries have expanded its healthcare business from providing 3rd party and 4th party logistics services to the entire end-to-end healthcare supply chain. HS Bio is also actively involved in managing an end-to-end supply chain of Covid-19 testing processes known as HealthChain.
HealthChain encompasses everything from the front-facing and back-end processes, physical logistics, digital healthcare platform, laboratory facilities, and research & development (“R&D”) services, as well as the provision of medical & healthcare supplies.
